healthcare investing Archives

Illustration of traders celebrating on a stock exchange floor beside a display showing Lycia Therapeutics (LYCA) up 67% in its IPO debut.

Lycia Therapeutics Stock Jumps 67% in IPO Debut as Wall Street Backs a New Approach to Allergy Treatment ( $BBC $IBB $LYCA $XBI )

by John F. Heerdink, Jr. October 25, 2026 500Views 0Likes

An upsized $317.5 million offering gives Lycia Therapeutics (NASDAQ: LYCA) fresh capital to pursue protein-degrading medicines, with early human data and 2027 clinical milestones sharpening the investment story. October 24, 2026 Wall Street has found a biotechnology company with an unusually literal…

Doctor reviewing healthcare data on a tablet beside a desktop displaying digital health tools at a hospital workstation

Doximity’s UpToDate Deal and Amwell’s Mental Health Results Build a Bullish Case for Connected Care -( $AMWL $DOCS $DCYHY $WTKWY )

by John F. Heerdink, Jr. October 21, 2026 547Views 0Likes

Clinical AI gains an authoritative partner as digital therapy delivers measurable results, giving investors fresh reasons to watch DOCS, AMWL, WKL and DCYHY. Healthcare technology has spent years promising to make medicine faster, smarter and less expensive. Two recent developments suggest parts…

Futuristic biotech illustration featuring a glowing digital bull, rising market arrows, and research pathways labeled Disc Medicine, Arcutis and Parabilis leading toward a biotechnology innovation hub.

Biotech Bulls Find Fresh Fuel as Disc Medicine, Arcutis and Parabilis Advance Their Investment Cases -( $ARQT $BBC $IRON $PBLS )

by John F. Heerdink, Jr. October 19, 2026 465Views 0Likes

A pivotal trial victory, a growing dermatology franchise and an approaching oncology catalyst put IRON, ARQT and PBLS in the spotlight, while the BBC biotech ETF offers a broader view of the sector. October 19, 2026 Biotechnology investors are being offered three…

Comic-style illustration of Michael J. Fox pointing toward Parkinson’s research and clinical trial displays, surrounded by scientists, patients and investors, with upward arrows symbolizing progress and investor optimism.

The Michael J. Fox Foundation Is Building Parkinson’s Next Chapter. Investors Have Reason to Pay Attention. -( $ABBV $IBB $SER $XBI )

by John F. Heerdink, Jr. October 8, 2026 473Views 0Likes

Better biomarkers, new FDA approvals and an emerging delivery pipeline strengthen the case for Parkinson’s innovation, with AbbVie and Serina Therapeutics offering distinct investment angles. The most compelling Parkinson’s investment story does not begin with a stock chart. It begins with a…

Zenflow’s $52 Million Raise Gives Its BPH Breakthrough Commercial Muscle -( $HSBC $TRIN )

by John F. Heerdink, Jr. October 7, 2026 342Views 0Likes

An exclusive U.S. distribution agreement with Cook Medical adds an established sales channel to Zenflow’s FDA-approved Spring System, and strengthens the case for a new approach to enlarged-prostate treatment. Zenflow has reached a consequential stage in the medical-device business: its technology is…

Trading-floor monitor displaying McKesson and Option Care Health logos, a $5.8 billion deal headline and an upward arrow representing home infusion growth.

McKesson’s $5.8 Billion Option Care Deal Puts Home Infusion in Wall Street’s Spotlight -( $MCK $OPCH )

by John F. Heerdink, Jr. October 6, 2026 931Views 0Likes

The proposed acquisition offers Option Care Health shareholders a substantial cash premium, and gives McKesson a strategic foothold in delivering complex therapies closer to patients. McKesson Corporation (NYSE: MCK) and private investment firm Clayton, Dubilier & Rice are making a $5.8 billion…

Iovance Biotherapeutics revenue guidance display in a modern trading-floor setting, highlighting rising Amtagvi demand, a Goldman Sachs Buy rating, and NASDAQ market screens.

Iovance Biotherapeutics Raises 2026 Revenue Guidance as Amtagvi Demand Accelerates & Goldman Resumes Coverage – ( $GS $IOVA $XBI $IBB )

by John F. Heerdink, Jr. September 30, 2026 508Views 0Likes

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) delivered the sort of update growth investors prefer: higher guidance, record revenue, expanding treatment access, and a more visible route toward operating leverage. Shares climbed sharply after the company lifted its 2026 revenue outlook, suggesting Wall Street is…

Investor-focused healthcare graphic showing a laboratory scene, a clinician holding a drug-delivery device, a glowing brain illustration, molecular imagery and a city skyline. The image highlights AbbVie Inc. (NYSE: ABBV) receiving FDA approval for JUVMO (tavapadon) for Parkinson’s disease and positions Serina Therapeutics Inc. (NYSE American: SER) and its SER-252 program as a potential next-generation therapy opportunity in advanced Parkinson’s disease.

AbbVie’s JUVMO Approval Puts Parkinson’s Innovation Back in Motion And Serina Therapeutics Has a Timely Opening -( $ABBV $AMRX $SER $SUPN $IBB $XBI )

by John F. Heerdink, Jr. September 29, 2026 582Views 0Likes

AbbVie Inc. (NYSE: ABBV) has secured (Sept. 28) FDA approval for JUVMO™ (tavapadon), a new once-daily Parkinson’s therapy, adding an important fresh option to a market long defined by the delicate art of managing motor symptoms, “OFF” time, dyskinesia and medication burden. For Serina…

Illustration of a brain transitioning from a cracked, burdened form to a vibrant neural network, symbolizing advanced Parkinson’s disease treatment innovation, continuous dopamine therapy and improved drug delivery.

Serina Therapeutics Advances SER-252 in Advanced Parkinson’s Disease as Continuous Therapy Market Expands -( $ABBV $SER )

by John F. Heerdink, Jr. September 25, 2026 561Views 0Likes

SER-252 enters Cohort 2 with blinded early observations that support the central premise: sustained delivery of a proven Parkinson’s medicine may be far more valuable when it asks less of patients and caregivers. In biotechnology, there are moonshots, and then there are…

Promotional graphic for Tribe Public’s CEO presentation and Q&A webinar, “A New Approach to Advanced Parkinson’s Disease: Exploring SER-252’s Clinical Progress,” featuring Serina Therapeutics CEO Steven Ledger; September 24, 2026, at 8:30 a.m. PT / 11:30 a.m. ET.

Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24

by John F. Heerdink, Jr. September 23, 2026 224Views 0Likes

Parkinson’s disease is one of medicine’s most stubborn commercial and scientific frontiers, and Serina Therapeutics, Inc. (NYSE American: SER) is positioning its lead program, SER-252, squarely in the middle of that opportunity. The clinical-stage biotechnology company has opened registration for a Tribe Public CEO…

Tag: healthcare investing

Lycia Therapeutics Stock Jumps 67% in IPO Debut as Wall Street Backs a New Approach to Allergy Treatment ( $BBC $IBB $LYCA $XBI )

Doximity’s UpToDate Deal and Amwell’s Mental Health Results Build a Bullish Case for Connected Care -( $AMWL $DOCS $DCYHY $WTKWY )

Biotech Bulls Find Fresh Fuel as Disc Medicine, Arcutis and Parabilis Advance Their Investment Cases -( $ARQT $BBC $IRON $PBLS )

The Michael J. Fox Foundation Is Building Parkinson’s Next Chapter. Investors Have Reason to Pay Attention. -( $ABBV $IBB $SER $XBI )

Zenflow’s $52 Million Raise Gives Its BPH Breakthrough Commercial Muscle -( $HSBC $TRIN )

McKesson’s $5.8 Billion Option Care Deal Puts Home Infusion in Wall Street’s Spotlight -( $MCK $OPCH )

Iovance Biotherapeutics Raises 2026 Revenue Guidance as Amtagvi Demand Accelerates & Goldman Resumes Coverage – ( $GS $IOVA $XBI $IBB )

AbbVie’s JUVMO Approval Puts Parkinson’s Innovation Back in Motion And Serina Therapeutics Has a Timely Opening -( $ABBV $AMRX $SER $SUPN $IBB $XBI )

Serina Therapeutics Advances SER-252 in Advanced Parkinson’s Disease as Continuous Therapy Market Expands -( $ABBV $SER )

Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24

Your Guide To Staying Informed In The Markets